Navigation Links
Amylin Pharmaceuticals to Present at BIOCOM Investor Conference

SAN DIEGO, Oct. 23 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will be presenting at the BIOCOM Investor Conference in San Diego on Tuesday, October 28, 2008 at 10:30 a.m. PT. Mark G. Foletta, Amylin's Senior Vice President of Finance and Chief Financial Officer, will be providing a corporate overview.

The live presentation will be Web cast, and a recording will be made available following the event. The Web cast and recording will be accessible through Amylin's corporate Web site, located at To access the live Web cast, please log on to Amylin's site approximately fifteen minutes prior to the presentation to register and download any necessary audio software.

About Amylin Pharmaceuticals

Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin's research and development activities leverage the company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California with over 2,000 employees nationwide. Further information on Amylin Pharmaceuticals is available at

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Lilly and Amylin Enter Into Supply Agreement for Exenatide Once Weekly
2. Amylin Pharmaceuticals Reports Third Quarter Financial Results
3. Amylin Pharmaceuticals to Webcast Third Quarter Results
4. Amylin Pharmaceuticals to Present at Thomas Weisel Healthcare, BioCentury NewsMakers, and Morgan Stanley Global Healthcare Conferences
5. Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA
6. Amylin and Lilly Set Date and Time for Conference Call
7. Amylin Pharmaceuticals to Webcast Second Quarter Results
8. Amylin Pharmaceuticals to Present at Goldman Sachs Global Healthcare Conference
9. Amylin Pharmaceuticals to Present Promising Data From Diabetes and Obesity Programs at ADA 2008
10. Amylin Pharmaceuticals to Present at Annual Meeting of Stockholders
11. Amylin Pharmaceuticals to Present at FBR Capital Markets Investor Conference
Post Your Comments:
(Date:11/25/2015)... November 25, 2015 Studies reveal ... human plaque and pave the way for more effective treatment ... cats     --> ... diagnosed health problems in cats, yet relatively little was understood ... collaborative studies have been conducted by researchers from the WALTHAM ...
(Date:11/25/2015)... 25, 2015 Orexigen® Therapeutics, Inc. (Nasdaq: ... a fireside chat discussion at the Piper Jaffray 27th ... . The discussion is scheduled for Wednesday, December 2, ... .  A replay will be available for 14 days ... , Julie NormartVP, Corporate Communications and Business Development , ...
(Date:11/24/2015)... 2015 Cepheid (NASDAQ: CPHD ) today ... following conference, and invited investors to participate via webcast. ...      Tuesday, December 1, 2015 at 11.00 a.m. Eastern Time ...      Tuesday, December 1, 2015 at 11.00 a.m. Eastern Time ... New York, NY      Tuesday, December 1, 2015 ...
(Date:11/24/2015)... 24, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: ... behalf of the Toronto Stock Exchange, confirms that as ... no corporate developments that would cause the recent movements ... --> About Aeterna Zentaris Inc. ... --> Aeterna Zentaris is a specialty biopharmaceutical company ...
Breaking Biology Technology:
(Date:11/12/2015)... 11, 2015   Growing need for low-cost, ... has been paving the way for use of ... discrete analytes in clinical, agricultural, environmental, food and ... used in medical applications, however, their adoption is ... to continuous emphasis on improving product quality and ...
(Date:11/10/2015)... Nov. 10, 2015 About ... that helps to identify and verify the identity ... considered as the secure and accurate method of ... a particular individual because each individual,s signature is ... especially when dynamic signature of an individual is ...
(Date:11/4/2015)... ALBANY, New York , November 4, 2015 /PRNewswire/ ... According to a new market report published by Transparency ... Size, Share, Growth, Trends and Forecast 2015 - 2022", ... value of US$ 30.3 bn by 2022. The market ... during the forecast period from 2015 to 2022. Rising ...
Breaking Biology News(10 mins):